The biotech sector is very defensive and non-cyclical due to the necessity of medications and healthcare treatment being largely independent of economic growth and market risk sentiment. Money is returning to the biotech sector as displayed by increased M&A activity and financing following the pandemic-driven bubble in the sector. Biotech is a blooming area of innovation and US productivity and is expected to grow at a 14% CAGR over the next decade.
The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.
The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump's election win on November 5, biotech ETFs like the iShares Biotechnology ETF NASDAQ: IBB and the SPDR Biotech ETF NYSE: XBI stopped short of new 52-week highs.
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
I reiterate a hold rating on IBB due to its stretched valuation at nearly 20x earnings and mixed technical situation. Despite a 7% YTD gain, IBB has underperformed the S&P 500, which is up 21%, and shows negative alpha. Key support and resistance levels to watch are $138-$141 and $150, respectively, with a potential bullish move to $160.
Making its debut on 02/05/2001, smart beta exchange traded fund iShares Biotechnology ETF (IBB) provides investors broad exposure to the Health Care ETFs category of the market.
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.
As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last Wednesday, several new opportunities and sector bull and bear markets might begin.
After a prolonged consolidation and downtrend following the pandemic-driven surge, the biotechnology sector is readying for a potential breakout and shifting its narrative. Represented by the iShares Biotechnology ETF NASDAQ: IBB, the sector has turned a significant corner, with previous resistance levels becoming support, setting the stage for a potential momentum shift.
Exchange-traded funds aren't just for risk-averse investors. Many funds can give exposure to some great growth stocks.
The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.